TELA Bio, Inc. announced that it has entered into a distribution agreement with Next Science, a medical technology company, granting TELA exclusive rights to sell and market Next Science's proprietary antimicrobial surgical wash with XBIO® technology across the US plastic reconstructive market. Additionally, TELA Bio received a first right of negotiation for the EU market upon successful CE approval. Next Science's XBIO Technology delivers an advanced option for surgical infection control by addressing the biofilms that make bacteria more resistant to traditional antimicrobial agents, disinfectants, and host immune defenses.

The no-rinse delivery allows the solution to provide over five hours of ongoing protection against bacterial biofilms. With no known bacterial resistance, the XBIO Technology provides broad spectrum efficacy with exceptional rates of pathogen removal.